

**RYAN M. CONRAD**  
The Brookings Institution  
1775 Massachusetts Avenue NW  
Washington, DC 20036  
Email: [rconrad@brookings.edu](mailto:rconrad@brookings.edu)

## **EDUCATION**

2010	Ph.D. in Economics, City University of New York Fields: Health, Labor, Applied Econometrics
2005	B.A. in Mathematics and Economics, Case Western Reserve University

## **EMPLOYMENT**

2025 – Present	Visiting Fellow, Center on Health Policy, Brookings Institution
2019 – 2025	Senior Economist, U.S. Food & Drug Administration, Center for Drug Evaluation and Research, Office of Strategic Programs
2018 – 2019	Special Advisor for Competition & Economics (Detail), U.S. Food & Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drug Policy
2012 – 2018	Economist, U.S. Food & Drug Administration, Center for Drug Evaluation and Research, Office of Strategic Programs
2011 – 2012	Visiting Scholar, University of Southern California, Schaeffer Center for Health Policy & Economics
2010 – 2012	AHRQ Postdoctoral Fellow of Health Services Research, University of California, Los Angeles and RAND Corporation
2005 – 2010	Research Analyst, National Bureau of Economic Research, Health Economics Program

## **BIBLIOGRAPHY**

- [1] Conrad R, Nance S, Tillman Z, Davis K. “Estimating cost savings from new generic drug approvals in 2022.” US Food & Drug Administration. Published online 2024.
- [2] “Office of Generic Drugs Annual Report.” Food & Drug Administration. Published online 2017 – 2024.
- [3] Conrad R, Davis K. “Estimating cost savings from new generic drug approvals in 2021.” US Food & Drug Administration. Published online 2023.

- [4] Conrad R, Davis K, Glos L, Liu W. “Estimating cost savings from new generic drug approvals in 2018, 2019, and 2020.” US Food and Drug Administration. Published online 2022.
- [5] Dezman Z, Stryckman B, Conrad R, et al. “Masking for COVID-19 is associated with decreased emergency department utilization for non-COVID viral illnesses and respiratory conditions in Maryland.” *The American Journal of Medicine*. 2021.
- [6] Conrad R, Lutter R. “Generic competition and drug prices: new evidence linking greater generic competition and lower generic drug prices.” US Food & Drug Administration. Published online 2019.
- [7] “Drug Shortages: Root Causes and Potential Solutions.” US Food & Drug Administration. Published online 2019..
- [8] Conrad R, Taylor K, Raggio M, et al. “Breakthrough therapy designation: CDER analysis of requests 4 years into the program.” *Therapeutic Innovation & Regulatory Science*. 2017.
- [9] Conrad R, Liu W, Nardinelli C, Lutter R. “Estimating cost savings from generic drug approvals in 2017.” Silver Spring, MD: US Food and Drug Administration. Published online 2017.
- [10] Goldman D, Dirani R, Fastenau J, Conrad R. “Do strict formularies replicate failure for patients with schizophrenia?” *The American Journal of Managed Care*. 2014.
- [11] Goldman D, Fastenau J, Dirani R, Conrad R, et al. “Medicaid prior authorization policies and imprisonment among patients with schizophrenia.” *The American Journal of Managed Care*. 2014.
- [12] Markowitz S, Cuellar A, Conrad R, Grossman M. “Alcohol control and foster care.” *Review of Economics of the Household*. 2014.
- [13] Turakhia M, Solomon M, Jhaveri M, Conrad R, et al. “Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation.” *American Heart Journal*. 2013.
- [14] Solomon M, Vijan S, Forma F, Conrad R, Summers N, Lakdawalla D. “The impact of insulin type on severe hypoglycemia events requiring inpatient and emergency department care in patients with type 2 diabetes.” *Diabetes Research and Clinical Practice*. 2013.
- [15] Turakhia M, Solomon M, Jhaveri M, Conrad R, et al. “Cardiovascular hospitalization is a strong predictor of mortality in Medicare beneficiaries with newly diagnosed atrial fibrillation.” *Journal of the American College of Cardiology*. 2012.
- [16] Solomon M, Vijan S, Forma F, Conrad R, Summers N, Lakdawalla D. “The impact of insulin type on severe hypoglycemia events requiring inpatient and emergency department care in patients with type 2 diabetes.” *Diabetes*. 2012.
- [17] Perlroth D, Conrad R, Cheung H, Lakdawalla D, White L. “ALS incidence and prevalence in the US: estimates from large administrative databases.” *European Journal of Neurology*. 2012.

[18] Best J, Romley J, Goldman D, Conrad R, Peters A. “Expenditures for Medicaid patients treated with exenatide compared with other diabetes management regimens.” The American Journal of Managed Care. 2012.

[19] Markowitz S, Cuellar A, Conrad R, Grossman M. “The effects of alcohol policies in reducing entry rates and time spent in foster care.” National Bureau of Economic Research; 2011.

[20] Markowitz S, Grossman M, Conrad R. “Chapter 2: Alcohol policies and child maltreatment. In: Current Issues in Health Economics.” Emerald Group Publishing Limited; 2010.

## **SELECTED FDA INITIATIVES**

Contributions as Senior Economist & Special Advisor, CDER

**Control of Nitrosamine Impurities in Human Drugs, 2024.** Led economic modeling to quantify the risk of shortages and price spikes under potential nitrosamine mitigation policy proposals.

**Inflation Reduction Act (IRA), 2022:** Led research efforts assessing market impacts of Medicare drug price negotiation and inflation rebates on competition, drug shortages, and manufacturer incentives, informing policy implementation.

**Prescription Drug User Fee Act (PDUFA) VI & VII, 2017, 2022:** Directed economic research to support negotiation and implementation, focusing on program efficiency and impact assessment of new review pathways.

**Generic Drug User Fee Act (GDUFA) II & III, 2017, 2022:** Developed key performance metrics and savings models to evaluate program success, enhance predictability, and support stakeholder communications.

**Coronavirus Aid, Relief, and Economic Security Act (CARES Act), 2020:** Led rapid economic assessments of therapeutic development incentives and supply chain provisions to support pandemic mitigation efforts.

**Over-The-Counter Monograph Reform (OMUFA), 2020:** Advised on economic frameworks for modernizing OTC review, assessing impacts of user fees on innovation and market dynamics under the CARES Act.

**Drug Competition Action Plan (DCAP), 2017:** Led economic analyses quantifying savings from generic entry to inform policy development addressing barriers to competition.

**21st Century Cures Act, 2016:** Evaluated economic implications of novel development pathways (e.g., Breakthrough Therapy) to support evidence-based regulatory decision-making.

## **SELECTED PRESENTATIONS AND PANELS**

GRx+Biosims Conference (2023), OGD-AAM Hatch-Waxman Workshop (2020, 2022), CDER@AEA Annual Meeting (2020), FDA-GPhA Quarterly Meetings (2015–2019), Brookings Institution (2015), ASHEcon Biennial Conference (2014, 2016), FTC (2014).

## **REFeree SERVICE**

BMJ; Health Affairs; Journal of General Internal Medicine; Therapeutic Innovation & Regulatory Science; The Review of Economics of the Household; BE Press: Forum for Health Economics & Policy.